tacalcitol
Small moleculeexperimental
Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic vitamin D3 analog. Tacalcitol is marketed under several names, including Curatoderm and Bonalfa. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00640822)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O- Mol. weight
- 416.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTacalcitol ↗
- ChEMBLCHEMBL2105611 ↗
Also known as
- 1,24-dihydroxycholecalciferol
- 1,24-dihydroxyvitamin d3
- 1 alpha,24-dihydroxycholecalciferol
- 1 alpha,24-dihydroxyvitamin d3
- 1 alpha,24-dihydroxyvitamin d3, (1alpha,3beta,5z,7e,24r)-isomer
- 1 alpha,24-dihydroxyvitamin d3, (1alpha,3beta,5z,7e,24s)-isomer
- (1 alpha,3 beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-1,3,24-triol
- curatoderm
- curatoderm
- curatoderm
- pri-2191
- tacalcitol
- tacalcitol
- tacalcitol
- tacalcitol
- tacalcitol
- tacalcitol
- tacalcitol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00670241 | Phase 3 | Apr 1, 2008 | Eastern Canada Cutaneous Research Associates Ltd., Leo Pharma |
| NCT00640822 | Phase 3 | Feb 1, 2008 | Leo Pharma, University of Dundee |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 2 | 2 | 1 | 2008 |
| Eastern Canada Cutaneous Research Associates Ltd. | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Dundee | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1